Please use this identifier to cite or link to this item:
https://scholarhub.balamand.edu.lb/handle/uob/6834
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Bindal, Poorva | en_US |
dc.contributor.author | Najjar, Mimi | en_US |
dc.contributor.author | Koehn, Kelly | en_US |
dc.contributor.author | Godara, Amandeep | en_US |
dc.contributor.author | Sborov, Douglas W | en_US |
dc.contributor.author | McClune, Brian | en_US |
dc.contributor.author | Julian, Kelley | en_US |
dc.contributor.author | Wagner, Charlotte | en_US |
dc.contributor.author | Mohyuddin, Ghulam Rehman | en_US |
dc.date.accessioned | 2023-05-29T09:47:33Z | - |
dc.date.available | 2023-05-29T09:47:33Z | - |
dc.date.issued | 2023-05-11 | - |
dc.identifier.issn | 10428194 | - |
dc.identifier.uri | https://scholarhub.balamand.edu.lb/handle/uob/6834 | - |
dc.language.iso | eng | en_US |
dc.publisher | National Library of Medicine | en_US |
dc.title | Refractoriness to last line of therapy: how often is it mandated and reported? A systematic review of randomized myeloma trials | en_US |
dc.type | Journal Article | en_US |
dc.identifier.doi | 10.1080/10428194.2023.2209682 | - |
dc.identifier.pmid | 37170589 | - |
dc.identifier.scopus | 2-s2.0-85159104222 | - |
dc.identifier.url | https://api.elsevier.com/content/abstract/scopus_id/85159104222 | - |
dc.contributor.affiliation | Faculty of Medicine | en_US |
dc.description.volume | 64 | en_US |
dc.description.issue | 7 | en_US |
dc.description.startpage | 1340 | en_US |
dc.description.endpage | 1343 | en_US |
dc.date.catalogued | 2023-05-29 | - |
dc.description.status | Published | en_US |
dc.identifier.ezproxyURL | http://ezsecureaccess.balamand.edu.lb/login?url=https://doi.org/10.1080/10428194.2023.2209682 | en_US |
dc.relation.ispartoftext | Leukemia and Lymphoma | en_US |
Appears in Collections: | Faculty of Medicine |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.